SMC Radiation Oncology SABR Cohort for Oligometastasis (SABR-OMOP)

Samsung Medical Center

Status: Enrolling

Conditions: ctDNA; Patient-Reported Outcomes (PRO); Oligoprogression; Stereotactic Body Radiation Therapy (SBRT); Oligometastasis

Treatments: Radiation: Stereotactic body radiotherapy (SBRT)

Study type: Observational

Funder types: Other

Identifiers

NCT07121335

SMC 2025-03-037

Details and patient eligibility

About

The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer.

The main questions it aims to answer are:

1. oncologic outcomes (progression-free survival, local failure rate),
2. patient-reported outcomes,
3. physician-assessed toxicity, and
4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Performance status (ECOG PS) 0-2
• Diagnosed with metastatic disease
• Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)

Exclusion criteria

• Patient with a history of prior radiotherapy to the site planned for SABR
• Patients with concomitant brain metastases